Abstract
Objective: The aim of this study was to evaluate the survival outcomes of radical prostatectomy (RP), external beam radiotherapy plus brachytherapy (EBRT + BT), and EBRT alone among elderly men (aged 70 years and above) with very high-risk (VHR) prostate cancer (PCa). Methods: We identified elderly men diagnosed with VHR PCa between 2004 and 2015 in the Surveillance, Epidemiology, and End Results database. The propensity score-matching method was adopted to balance the covariates and generate new cohorts. Kaplan-Meier and Cox analyses were conducted to build up survival curves and evaluate the overall survival (OS) and PCa-specific survival (PCSS) outcomes. Results: A total of 9,818 patients were identified. Of them, 5,839 were in the EBRT group, 725 in the EBRT + BT group, and 3,254 in the RP group. The survival curves of the overall cohort showed that RP was associated with the best OS, followed by EBRT + BT and EBRT (p < 0.001). As for the PCSS, RP shared similar outcomes with EBRT + BT (hazard ratio [HR]: 1.25 [0.93–1.69], p = 0.175). EBRT was associated with significantly worse PCSS than both RP (HR: 1.88, 95% confidence interval [95% CI] [1.64–2.15], p < 0.001) and EBRT + BT (HR: 1.48, 95% CI [1.19–1.85], p = 0.002). In the matched cohorts, RP presented better OS (HR: 1.41, 95% CI [1.07–1.86], p = 0.041) and similar PCSS with EBRT + BT (HR: 1.50, 95% CI [0.91–2.47], p = 0.12). RP was associated with significantly better OS and PCSS outcomes than EBRT alone (OS HR: 1.58, 95% CI [1.59–2.12], p < 0.001; PCSS HR: 2.08 [1.60–2.72], p < 0.001). EBRT + BT also had significantly better OS and PCSS outcomes than EBRT alone (OS HR: 1.33, 95% CI [1.11–1.60], p < 0.001; PCSS HR: 1.57 [1.13–2.19], p = 0.003). Conclusions: For patients above 70 years with VHR PCa, RP was associated with better OS and similar PCSS than EBRT + BT. Both RP and EBRT + BT have better OS and PCSS than EBRT alone.
Journal Section:
Editor's choice
References
1.
Jemal
A
, Siegel
R
, Xu
J
, Ward
E
. Cancer statistics, 2010
. CA Cancer J Clin
. 2010 Sep–Oct
;60
(5
):277
–300
.2.
Ferlay
J
, Soerjomataram
I
, Dikshit
R
, Eser
S
, Mathers
C
, Rebelo
M
, . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
. Int J Cancer
. 2015 Mar 1
;136
(5
):E359
–86
.3.
Torre
LA
, Siegel
RL
, Ward
EM
, Jemal
A
. Global cancer incidence and mortality rates and trends: an update
. Cancer Epidemiol Biomarkers Prev
. 2016 Jan
;25
(1
):16
–27
.4.
Mohler
JL
, Antonarakis
ES
, Armstrong
AJ
, D’Amico
AV
, Davis
BJ
, Dorff
T
, . Prostate cancer, Version 2.2019, NCCN clinical practice guidelines in oncology
. J Natl Compr Canc Netw
. 2019 May 1
;17
(5
):479
–505
.5.
Yang
DD
, Muralidhar
V
, Nguyen
PL
, Buzurovic
I
, Martin
NE
, Mouw
KW
, . Lack of benefit from the addition of external beam radiation therapy to brachytherapy for intermediate- and high-risk prostate cancer
. Int J Radiat Oncol Biol Phys
. 2017 Nov 15
;99
(4
):904
–11
.6.
Kishan
AU
, Cook
RR
, Ciezki
JP
, Ross
AE
, Pomerantz
MM
, Nguyen
PL
, . Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with gleason score 9–10 prostate cancer
. JAMA
. 2018 Mar 6
;319
(9
):896
–905
.7.
Wedde
TB
, Småstuen
MC
, Brabrand
S
, Fosså
SD
, Kaasa
S
, Tafjord
G
, . Ten-year survival after high-dose-rate brachytherapy combined with external beam radiation therapy in high-risk prostate cancer: a comparison with the Norwegian SPCG-7 cohort
. Radiother Oncol
. 2019 Mar
;132
:211
–7
.8.
Challapalli
A
, Jones
E
, Harvey
C
, Hellawell
GO
, Mangar
SA
. High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancer
. Br J Radiol
. 2012 Nov
;85 Spec No 1
(Spec Iss 1
):S18
–27
.9.
Hoskin
PJ
, Rojas
AM
, Bownes
PJ
, Lowe
GJ
, Ostler
PJ
, Bryant
L
. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer
. Radiother Oncol
. 2012 May
;103
(2
):217
–22
.10.
Joseph
N
, Taylor
C
, O’Hara
C
, Choudhury
A
, Elliott
T
, Logue
J
, . A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients
. Radiother Oncol
. 2016
;121
(2
):299
–303
.11.
Schlussel Markovic
E
, Buckstein
M
, Stone
NN
, Stock
RG
. Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy
. BJU Int
. 2018 May
;121
(5
):774
–80
.12.
Tharmalingam
H
, Tsang
Y
, Choudhury
A
, Alonzi
R
, Wylie
J
, Ahmed
I
, . External beam radiation therapy (EBRT) and high-dose-rate (HDR) brachytherapy for intermediate and high-risk prostate cancer: the impact of EBRT volume
. Int J Radiat Oncol Biol Phys
. 2020 Mar 1
;106
(3
):525
–33
.13.
Ennis
RD
, Hu
L
, Ryemon
SN
, Lin
J
, Mazumdar
M
. Brachytherapy-based radiotherapy and radical prostatectomy are associated with similar survival in high-risk localized prostate cancer
. J Clin Oncol
. 2018 Apr 20
;36
(12
):1192
–8
.14.
Berg
S
, Cole
AP
, Krimphove
MJ
, Nabi
J
, Marchese
M
, Lipsitz
SR
, . Comparative effectiveness of radical prostatectomy versus external beam radiation therapy plus brachytherapy in patients with high-risk localized prostate cancer
. Eur Urol
. 2019 Apr
;75
(4
):552
–5
.15.
Tilki
D
, Chen
MH
, Wu
J
, Huland
H
, Graefen
M
, Braccioforte
M
, . Surgery vs radiotherapy in the management of biopsy gleason score 9–10 prostate cancer and the risk of mortality
. JAMA Oncol
. 2019 Feb 1
;5
(2
):213
–20
.16.
Bechis
SK
, Carroll
PR
, Cooperberg
MR
. Impact of age at diagnosis on prostate cancer treatment and survival
. J Clin Oncol
. 2011 Jan 10
;29
(2
):235
–41
.17.
D’Amico
AV
, Whittington
R
, Malkowicz
SB
, Schultz
D
, Blank
K
, Broderick
GA
, . Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
. JAMA
. 1998 Sep 16
;280
(11
):969
–74
.18.
Thompson
I
, Thrasher
JB
, Aus
G
, Burnett
AL
, Canby-Hagino
ED
, Cookson
MS
, . Guideline for the management of clinically localized prostate cancer: 2007 update
. J Urol
. 2007 Jun
;177
(6
):2106
–31
.19.
Heidenreich
A
, Bastian
PJ
, Bellmunt
J
, Bolla
M
, Joniau
S
, van der Kwast
T
, . EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013
. Eur Urol
. 2014 Jan
;65
(1
):124
–37
.20.
Sundi
D
, Wang
VM
, Pierorazio
PM
, Han
M
, Bivalacqua
TJ
, Ball
MW
, . Very-high-risk localized prostate cancer: definition and outcomes
. Prostate Cancer Prostatic Dis
. 2014 Mar
;17
(1
):57
–63
.21.
Joniau
S
, Briganti
A
, Gontero
P
, Gandaglia
G
, Tosco
L
, Fieuws
S
, . Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study
. Eur Urol
. 2015 Jan
;67
(1
):157
–64
.22.
Muralidhar
V
, Chen
MH
, Reznor
G
, Moran
BJ
, Braccioforte
MH
, Beard
CJ
, . Definition and validation of “favorable high-risk prostate cancer”: implications for personalizing treatment of radiation-managed patients
. Int J Radiat Oncol Biol Phys
. 2015 Nov 15
;93
(4
):828
–35
.23.
Beltran
H
, Tomlins
S
, Aparicio
A
, Arora
V
, Rickman
D
, Ayala
G
, . Aggressive variants of castration-resistant prostate cancer
. Clin Cancer Res
. 2014 Jun 1
;20
(11
):2846
–50
.24.
Mano
R
, Eastham
J
, Yossepowitch
O
. The very-high-risk prostate cancer: a contemporary update
. Prostate Cancer Prostatic Dis
. 2016 Dec
;19
(4
):340
–8
.25.
Muralidhar
V
, Mahal
BA
, Butler
S
, Lamba
N
, Yang
DD
, Leeman
J
, . Combined external beam radiation therapy and brachytherapy versus radical prostatectomy with adjuvant radiation therapy for gleason 9-10 prostate cancer
. J Urol
. 2019 Nov
;202
(5
):973
–8
.26.
Yin
M
, Zhao
J
, Monk
P
, Martin
D
, Folefac
E
, Joshi
M
, . Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in high-risk localized prostate cancer
. Cancer Med
. 2020 Jan
;9
(1
):27
–34
.27.
Zelefsky
MJ
, Eastham
JA
, Cronin
AM
, Fuks
Z
, Zhang
Z
, Yamada
Y
, . Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix
. J Clin Oncol
. 2010 Mar 20
;28
(9
):1508
–13
.28.
Boorjian
SA
, Karnes
RJ
, Viterbo
R
, Rangel
LJ
, Bergstralh
EJ
, Horwitz
EM
, . Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer
. Cancer
. 2011 Jul 1
;117
(13
):2883
–91
.29.
Bandini
M
, Pompe
RS
, Marchioni
M
, Tian
Z
, Gandaglia
G
, Fossati
N
, . Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis
. World J Urol
. 2018 Jan
;36
(1
):7
–13
.30.
Dayes
IS
, Parpia
S
, Gilbert
J
, Julian
JA
, Davis
IR
, Levine
MN
, . Long-term results of a randomized trial comparing iridium implant plus external beam radiation therapy with external beam radiation therapy alone in node-negative locally advanced cancer of the prostate
. Int J Radiat Oncol Biol Phys
. 2017 Sep 1
;99
(1
):90
–3
.31.
Morris
WJ
, Tyldesley
S
, Rodda
S
, Halperin
R
, Pai
H
, McKenzie
M
, . Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer
. Int J Radiat Oncol Biol Phys
. 2017 Jun 1
;98
(2
):275
–85
.32.
Strouthos
I
, Chatzikonstantinou
G
, Zamboglou
N
, Milickovic
N
, Papaioannou
S
, Bon
D
, . Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer
. Radiother Oncol
. 2018 Aug
;128
(2
):301
–7
.33.
Wedde
TB
, Småstuen
MC
, Brabrand
S
, Fosså
SD
, Kaasa
S
, Tafjord
G
, . Ten-year survival after high-dose-rate brachytherapy combined with external beam radiation therapy in high-risk prostate cancer: a comparison with the Norwegian SPCG-7 cohort
. Radiother Oncol
. 2019 Mar
;132
:211
–7
.34.
Fuks
Z
, Leibel
SA
, Wallner
KE
, Begg
CB
, Fair
WR
, Anderson
LL
, . The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation
. Int J Radiat Oncol Biol Phys
. 1991 Aug
;21
(3
):537
–47
.© 2021 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2021
You do not currently have access to this content.
